(Q41321697)

29 September 2017

1 reference

title

Current management of onychomycosis. An overview (English)

1 reference

29 September 2017

1

1 reference

29 September 2017

Scher RK

2

1 reference

29 September 2017

De Doncker P

series ordinal

3

1 reference

29 September 2017

publication date

1 January 1997

1 reference

29 September 2017

1 reference

29 September 2017

volume

15

1 reference

29 September 2017

issue

1

1 reference

29 September 2017

page(s)

121-135

1 reference

Ciclopirox olamine: A hydroxypyridone antifungal agent

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Preliminary report on use of carbon dioxide laser in podiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Open randomized comparison of itraconazole versus terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Onychomycosis Treated with Itraconazole or Griseofulvin Alone with and without a Topical Antimycotic or Keratolytic Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

A comparative study of the immunologic properties of hoof and nail fibrous proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Partial surgical avulsion of the nail in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Treatment of onychomycosis with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Pharmacology of the allylamines

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Pharmacokinetic profile of orally administered itraconazole in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

In vitro activity of terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

The ultrastructure and growth of human nails

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Acquired nail beading in patients receiving itraconazole--an indicator of faster nail growth? A study using optical profilometry

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Candidiasis endocrinopathy syndrome. Treatment with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Onychomycosis and AIDS: treatment with topical ciclopirox olamine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Trichophyton rubrum infection in families.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

In vitro studies with R 51,211 (itraconazole)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Activity of triazole derivatives against Pityrosporum orbiculare in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Percutaneous Absorption. On the Relevance of in Vitro Data

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Antifungal susceptibility tests

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Vitamin E and onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Future directions of antifungal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Antifungal agents: an overview. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Onychomycosis. Agents of choice.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

An evaluation of itraconazole in the management of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Tioconazole nail solution--an open study of its efficacy in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Treatment of dermatomycoses and onychomycoses--state of the art

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

The topical treatment of onychomycosis using a new combined urea/imidazole preparation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Treatment of onychomycosis with nail avulsion and topical ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Treatment of onychomycosis by ODT therapy with 20% urea ointment and 2% tolnaftate ointment

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Antifungal Activity of Tioconazole (UK-20,349), a New Imidazole Derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Nail is produced by the normal nail bed: a controversy resolved

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Determinants of nail thickness and length

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Testing of organisms for susceptibility to triazoles: is it justified?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Acidic and basic hair/nail ("hard") keratins: their colocalization in upper cortical and cuticle cells of the human hair follicle and their relationship to "soft" keratins

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Fluconazole in the treatment of severe onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Onychomycosis: successful treatment with once-weekly fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Non-Traumatic Removal of the Nail and Simultaneous Treatment of Onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Terbinafine in onychomycosis with involvement by non-dermatophytic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Antifungal activity of the allylamine derivative terbinafine in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Activity of terbinafine in experimental fungal infections of laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Efficacy and safety of itraconazole in the long-term treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Preclinical data and mode of action of amorolfine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Kinetics of amorolfine in human nails.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Treatment of Onychomycosis by Partial Nail Avulsion and Topical Miconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Percutaneous absorption of amorolfine following a single topical application of an amorolfine cream formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

New approaches to the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Terbinafine: mode of action and properties of the squalene epoxidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Successful treatment of Aspergillus flavus onychomycosis with oral itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Inactivity of terbinafine in a rat model of pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Single dose treatment of fungal nail disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Synthesis and structure-activity correlations within allylamine antimycotics

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Treatment of superficial onychomycosis with topically applied glutaraldehyde. A preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Oral, topical and parenteral antifungal treatment with itraconazole in normal and in immunocompromised animals

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Biochemical approaches to selective antifungal activity. Focus on azole antifungals

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

A randomized treatment duration-finding study of terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Clinical efficacy and tolerability of terbinafine (Lamisil)--a new topical and systemic fungicidal drug for treatment of dermatomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Special features of the clinical use of oral terbinafine in the treatment of fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

The treatment of fungus and yeast infections of nails by the method of "chemical removal'

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Bioavailability of fluconazole in the skin after oral medication

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Very short duration therapy with oral terbinafine for fingernail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970420-4

7 January 2021

10.1016/S0733-8635(05)70420-4

Identifiers

DOI

1 reference

29 September 2017

1 reference